Minerva Neurosciences announces pricing of initial public
offering
01/07/2014 18:02
Minerva Neurosciences, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases, today announced the pricing of its initial public offering of 5,454,545 shares of its common stock at a public offering price of USD 6.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "NERV" on July 1, 2014. In addition, Minerva has granted the underwriters a 30-day option to purchase up to an additional 818,181 shares of common stock at the same price. The offering is expected to close on July 7, 2014, subject to customary closing conditions. Jefferies LLC is acting as sole book-running manager for the offering. Robert W. Baird & Co. Incorporated and JMP Securities LLC are acting as co-managers.
01/07/2014 18:02
Minerva Neurosciences, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases, today announced the pricing of its initial public offering of 5,454,545 shares of its common stock at a public offering price of USD 6.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "NERV" on July 1, 2014. In addition, Minerva has granted the underwriters a 30-day option to purchase up to an additional 818,181 shares of common stock at the same price. The offering is expected to close on July 7, 2014, subject to customary closing conditions. Jefferies LLC is acting as sole book-running manager for the offering. Robert W. Baird & Co. Incorporated and JMP Securities LLC are acting as co-managers.
